These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

715 related items for PubMed ID: 24172843

  • 1. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.
    Gouin-Thibault I, Flaujac C, Delavenne X, Quenet S, Horellou MH, Laporte S, Siguret V, Lecompte T.
    Thromb Haemost; 2014 Feb; 111(2):240-8. PubMed ID: 24172843
    [Abstract] [Full Text] [Related]

  • 2. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
    Barrett YC, Wang Z, Frost C, Shenker A.
    Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
    [Abstract] [Full Text] [Related]

  • 3. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide.
    Douxfils J, Chatelain C, Chatelain B, Dogné JM, Mullier F.
    Thromb Haemost; 2013 Aug; 110(2):283-94. PubMed ID: 23765180
    [Abstract] [Full Text] [Related]

  • 4. Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme.
    Van Blerk M, Bailleul E, Chatelain B, Demulder A, Devreese K, Douxfils J, Jacquemin M, Jochmans K, Mullier F, Wijns W, China B, Vernelen K, Soumali MR.
    Int J Lab Hematol; 2017 Aug; 39(4):402-408. PubMed ID: 28304137
    [Abstract] [Full Text] [Related]

  • 5. Sensitivity of routine coagulation assays to direct oral anticoagulants: patient samples versus commercial drug-specific calibrators.
    Lim MS, Chapman K, Swanepoel P, Enjeti AK.
    Pathology; 2016 Dec; 48(7):712-719. PubMed ID: 27780603
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents.
    Dale BJ, Ginsberg JS, Johnston M, Hirsh J, Weitz JI, Eikelboom JW.
    J Thromb Haemost; 2014 Nov; 12(11):1810-5. PubMed ID: 25196577
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study.
    Gouin-Thibault I, Freyburger G, de Maistre E, Susen S, Delavenne X, Golmard JL, Gruel Y, Sié P, GFHT study group on DOAC.
    Thromb Res; 2017 Oct; 158():126-133. PubMed ID: 28892657
    [Abstract] [Full Text] [Related]

  • 9. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.
    Bonar R, Favaloro EJ, Mohammed S, Ahuja M, Pasalic L, Sioufi J, Marsden K.
    Pathology; 2016 Jan; 48(1):60-71. PubMed ID: 27020211
    [Abstract] [Full Text] [Related]

  • 10. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
    Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E.
    Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
    [Abstract] [Full Text] [Related]

  • 11. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays.
    Hillarp A, Gustafsson KM, Faxälv L, Strandberg K, Baghaei F, Fagerberg Blixter I, Berndtsson M, Lindahl TL.
    J Thromb Haemost; 2014 Sep; 12(9):1545-53. PubMed ID: 24965851
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
    Testa S, Legnani C, Tripodi A, Paoletti O, Pengo V, Abbate R, Bassi L, Carraro P, Cini M, Paniccia R, Poli D, Palareti G.
    J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988
    [Abstract] [Full Text] [Related]

  • 17. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.
    Becker RC, Alexander JH, Newby LK, Yang H, Barrett Y, Mohan P, Wang J, Harrington RA, Wallentin LC.
    Thromb Haemost; 2010 Nov; 104(5):976-83. PubMed ID: 20806117
    [Abstract] [Full Text] [Related]

  • 18. Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting.
    Antovic A, Norberg EM, Berndtsson M, Rasmuson A, Malmström RE, Skeppholm M, Antovic J.
    Thromb Haemost; 2017 Aug 30; 117(9):1700-1704. PubMed ID: 28640321
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.